Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
University of Washington
University of Washington
SystImmune Inc.
Toray Industries, Inc
Instituto do Cancer do Estado de São Paulo
National Cancer Institute (NCI)
Tempus AI